Immunomodulation for Corneal Transplantation

  • Douglas J. Coster
  • Keryn A. Williams
Part of the Essentials in Ophthalmology book series (ESSENTIALS)


Corneal Transplantation Corneal Graft Systemic Immunosuppression Corneal Allograft Corneal Graft Rejection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    http://www. Anzdata. Org. Au/ANZDATA/anzdatawelcome. HtmGoogle Scholar
  2. 2.
    Opelz G (1994) Effect of the maintenance immunosuppressive drug regiment on kidney transplant outcome. Transplantation 58:443–446PubMedGoogle Scholar
  3. 3.
    Williams KA, Muehlberg SM, Bartlett CM, Esterman A, Coster DJ (2000) Report from the Australian Corneal Graft Registry 1999. Snap Printing, Adelaide, pp 1–137Google Scholar
  4. 4.
    Grabner G, Zehetbauer G, Bettelheim H, Honigsmann C, Dorda W (1978) The blood-aqueous barrier and its permeability for proteins of different molecular weight. Graefes Arch Klin Exp Ophthalmol 207:137–148CrossRefGoogle Scholar
  5. 5.
    Dernouchamps JP, Heremans JF (1975) Molecular sieve effect of the blood-aqueous barrier. Exp Eye Res 21:289–297CrossRefPubMedGoogle Scholar
  6. 6.
    Maurice D, Mishima S (1984) Ocular pharmacokinetics. In: Sears M (ed) Pharmacology of the eye. Springer, Berlin Heidelberg New York, pp 19–116Google Scholar
  7. 7.
    Kuchle M, Nguyen NX, Naumann GO (1994) Aqueous flare following penetrating keratoplasty and in corneal graft rejection. Arch Ophthalmol 112:354–358PubMedGoogle Scholar
  8. 8.
    Barker CF, Billingham RE (1973) Immunologically privileged sites and tissues. In: Porter R, Knight J (eds) Corneal graft failure. CIBA Foundation Symposium 15 (new series). Elsevier, Amsterdam; Excerpta Medica, North-Holland, pp 79–104Google Scholar
  9. 9.
    Medawar P (1948) Immunity of homologous grafted skin III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58–69Google Scholar
  10. 10.
    Collin HB (1996) Endothelial cell lined lymphatics in the vascularized rabbit cornea. Invest Ophthalmol 5:337–354Google Scholar
  11. 11.
    Whitsett CF, Stulting RD (1984) The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Vis Sci 25:519–524PubMedGoogle Scholar
  12. 12.
    Nelken E, Michaelson IC, Nelken D, Gurebitch J (1956) ABO antigens in the human cornea. Nature 177:840Google Scholar
  13. 13.
    Salisbury JD, Gebhardt BM (1981) Blood group antigens on human corneal cells demonstrated by immunoperoxidase staining. Am J Ophthalmol 91:46–50PubMedGoogle Scholar
  14. 14.
    Katami M, Madden PW, White DJ, Watson PG, Kamada N (1989) The extent of immunological privilege of orthotopic corneal grafts in the inbred rat. Transplantation 41:371–376Google Scholar
  15. 15.
    Williams KA, Ash JK, Coster DJ (1985) Histocompatability antigen and passenger cell content of normal and diseased human cornea. Transplantation 39:265–269PubMedGoogle Scholar
  16. 16.
    Catry L, Van den Oord J, Foets B, Missotten L (1991) Morphologic and immunophenotypic heterogeneity of corneal dendritic cells. Graefes Arch Clin Ex Ophthalmol 229:182–185Google Scholar
  17. 17.
    Jager MJ (1992) Corneal Langerhans cells and ocular immunology. Reg Immunol 4:186–195PubMedGoogle Scholar
  18. 18.
    Baudouin C, Brignole F, Pisella PJ, Becquet F, Philip PJ (1997) Immunophenotyping of human dendriform cells from the conjunctival epithelium. Curr Eye Res 16:475–481CrossRefPubMedGoogle Scholar
  19. 19.
    Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR (2002) Draining lymph evidence for major histocompatibility complex (MHC) Class II-positive cells derived from Class II-negative grafts. J Exp Med 195:259–268PubMedGoogle Scholar
  20. 20.
    Hamrah P, Zhang Q, Liu Y, Dana MR (2002) Novel characterization of MHC Class II-negative population of resident corneal Langerhans celltype dendritic cells. Invest Ophthalmol Vis Sci 43:639–646PubMedGoogle Scholar
  21. 21.
    Wilson SE, Li Q, Weng J, Barry-Lane PA, Jester JV, Liang Q et al. (1996) The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest Ophthalmol Vis Sci 37:1582–1592PubMedGoogle Scholar
  22. 22.
    Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA (1996) CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5:7–16CrossRefPubMedGoogle Scholar
  23. 23.
    Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Fergusin TA (1997) CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 99:396–402PubMedGoogle Scholar
  24. 24.
    Wilbanks GA, Mammolenti M, Streilein JW (1992) Studies on the induction of anterior chamber-associated immune deviation (ACAID), III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol 22:165–173PubMedGoogle Scholar
  25. 25.
    D'Orazio T, Niederkorn JY (1998) A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol 160:2089–2098PubMedGoogle Scholar
  26. 26.
    Taylor AW, Streilein JW, Cousins SW (1994) Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. Neuroimmunomodulation 1:188–194PubMedGoogle Scholar
  27. 27.
    Taylor AW, Streilein JW, Cousins SW (1994) Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol 153:1080–1086PubMedGoogle Scholar
  28. 28.
    Streilein JW (1996) Peripheral tolerance induction: lessons from immune privileged sites and tissues. Transplant Proc 28:2066–2070PubMedGoogle Scholar
  29. 29.
    Williams KA, Coster DJ (1997) Rethinking immunological privilege: implications for corneal and limbal stem cell transplantation. Mol Med Today 3:495–515PubMedGoogle Scholar
  30. 30.
    Coster DJ (1981) Factors affecting the outcome of corneal transplantation. Ann R Coll Surg Engl 63:91–97PubMedGoogle Scholar
  31. 31.
    Collin HB (1966) Endothelial cell lines lymphatics in the vascularized rabbit cornea. Invest Ophthalmol 5:337–354PubMedGoogle Scholar
  32. 32.
    Cursiefen C, Schlötzer-Schrehardt V, Küchle M et al. (2002) Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci 43:2127–2135PubMedGoogle Scholar
  33. 33.
    Treselet PA, Foulks GN, Sanfilippo F (1984) The expression of HLA antigens by cells in the human cornea. Am J Ophthalmol 98:763–772PubMedGoogle Scholar
  34. 34.
    Pepose JS, Gardner KM, Nestor MS, Foos RY, Pettit Th (1985) Detection of HLA class I and II antigens in rejected human corneal allografts. Ophthalmology 92:1480–1484PubMedGoogle Scholar
  35. 35.
    Williams KA, White MA, Ash JK, Coster DJ (1989) Leukocytes in the graft bed associated with corneal graft failure. Analysis by immunohistology and actuarial graft survival. Ophthalmology 96:38–44PubMedGoogle Scholar
  36. 36.
    Knop N, Knop E (2000) Conjunctiva-associated lymphoid tissue in the human eye. Invest Ophthalmol Vis Sci 4:1270–1279Google Scholar
  37. 37.
    Porgador A, Staats HF, Itoh Y, Kelsall BL (1998) Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptidepresenting dendritic cells in nasal mucosal-associated lymphoid tissue. Infect Immunol 66:5876–5881Google Scholar
  38. 38.
    Chen H, Hendricks RL (1998) B7 costimulatory requirements of T cells at an inflammatory site. J Immunol 160:5045–5052PubMedGoogle Scholar
  39. 39.
    Klebe S, Sykes P, Coster D, Krishnan R, Williams K (2001) Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine interleukin 10 to donor corneal endothelium. Transplantation 15:1214–1220CrossRefGoogle Scholar
  40. 40.
    McMenamin PG, Crewe J, Morrison S, Holt PG (1994) Immunomorphologic studies of macrophages and MHC Class II-positive dendritic cells in the iris and ciliary body of the rat, mouse, and human eye. Invest Ophthalmol Vis Sci 35:3234–3250PubMedGoogle Scholar
  41. 41.
    Streilein JW (1996) Peripheral tolerance induction: lessons from immune privileged sites and tissues. Transplant Proc 28:2066–2070PubMedGoogle Scholar
  42. 42.
    Egan RM, Yorkey C, Black R, Loh WK, Stevens JL, Woodward JG (1996) Peptide-specific T cell clonal expansion in vivo following immunization in the eye, an immune-privileged site. J Immunol 157:2262–2271PubMedGoogle Scholar
  43. 43.
    Williamson JS, Di Marco S, Streilein JW (1987) Immunobiology of Langerhans cells on the ocular surface. I Langerhans cells within the central cornea interfere with induction of anterior chamber associated immune deviation. Invest Ophthalmol Vis Sci 28:1527–1532PubMedGoogle Scholar
  44. 44.
    Yamagami S, Dana MR (2001) The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci 42:1293–1298PubMedGoogle Scholar
  45. 45.
    Ayliffe W, Alam Y, Bell EB, McLeod D, Hutchinson IV (1992) Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol 76:602–606PubMedGoogle Scholar
  46. 46.
    Joo CK, Pepose JS, Stuart PM (1995) T-cell mediated responses in a murine model of orthotopic corneal transplantation. Invest Ophthalmol Vis Sci 36:1530–1540PubMedGoogle Scholar
  47. 47.
    Katami M (1995) The mechanisms of corneal graft failure in the rat. Eye 9:197–207PubMedGoogle Scholar
  48. 48.
    Yamada J, Kurimoto I, Streilein JW (1999) Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci 40:2614–2621PubMedGoogle Scholar
  49. 49.
    Callanan DG, Luckenback MW, Fischer BJ, Peeler JS, Niederkorn JY (1989) Histopathology of rejected orthotopic corenal grafts in the rat. Invest Ophthalmol Vis Sci 30:413–424PubMedGoogle Scholar
  50. 50.
    Larkin DFP, Alexander RA, Cree IA (1997) Infiltrating inflammatory cell phenotypes and apoptosis in rejected human corneal allografts. Eye 11:68–74PubMedGoogle Scholar
  51. 51.
    Kuffova L, Holan V, Lumsden L, Forrester JV, Filipec M (1999) Cell sub-populations in failed human corneal grafts. Br J Ophthalmol 83:1364–1369PubMedGoogle Scholar
  52. 52.
    Matoba AY, Peeler JS, Niederkorn JY (1986) T cell subsets in the immune rejection of murine heterotopic corneal allografts. Invest Ophthalmol Vis Sci 27:1244–1254PubMedGoogle Scholar
  53. 53.
    Hegde S, Niederkorn JY (2000) The role of cytotoxic T lymphocytes in corneal allograft rejection. Invest Ophthalmol Vis Sci 41:3341–3347PubMedGoogle Scholar
  54. 54.
    Jager MJ, Volker-Dieben HJ, Vos A, Broersma L, Kok FG, van der Gaag R (1991) Cellular and humoral anticorneal immune response in corneal transplantation. Arch Ophthalmol 109:972–977PubMedGoogle Scholar
  55. 55.
    Hutchinson IV, Alam Y, Ayliffe WR (1995) The humoral response to an allograft. Eye 9:155–160PubMedGoogle Scholar
  56. 56.
    Goslings WR, Yamada J, Dana MR et al. (1999) Corneal transplantation in antibody-deficient hosts. Invest Ophthalmol Vis Sci 40:250–253PubMedGoogle Scholar
  57. 57.
    Tuft SJ, Coster DJ (1990) The corneal endothelium. Eye 4:389–424PubMedGoogle Scholar
  58. 58.
    The Collaborative Corneal Transplantation Studies Research Group (1992) The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in highrisk corneal transplantation. Arch Ophthalmol 110:1392–1403Google Scholar
  59. 59.
    Hopkins KA, Maguire MG, Fink NE, Bias WB (1992) Reproducibility of HLA-A,-B, and-DR typing using peripheral blood samples; results of retyping in the collaborative corneal transplant studies. Corneal Transplantation Studies Group (corrected). Hum Immunol 33:122–128CrossRefPubMedGoogle Scholar
  60. 60.
    Batchelor JR, Casey TA, Werb A, et al. (1976) HLA matching and corneal grafting. Lancet 1:551–554CrossRefPubMedGoogle Scholar
  61. 61.
    Volker-Dieben HJ, Kok-van Alphen CC, Lansbergen Q, Persijn GG (1982) The effect of prospective HLA-A and-B matching and corneal graft survival. Acta Ophthalmol (Copenhagen) 60:203–212Google Scholar
  62. 62.
    Gore SM, Vail A, Bradley VA, Rogers CA, Easty DL, Armitage WJ (1995) HLA-DR matching in corneal transplantation. Systemic review of published evidence. Corneal Transplant Follow-up Study Collaborators. Transplantation 60:1033–1039PubMedGoogle Scholar
  63. 63.
    Foulks GN, Sanfilippo FP, Locascio JA III, Mac-Queen JM, Dawson DV (1983) Histocompatability testing for keratoplasty in high-risk patients. Ophthalmology 90:230–244PubMedGoogle Scholar
  64. 64.
    Sanfilippo F, MacQueen JM, Vaughn WK, Foulks GN (1986) Reduced graft rejection with good HLA-A and B matching in high-risk corneal transplantation. N Engl J Med 315:29–35PubMedGoogle Scholar
  65. 65.
    Hoffman F, von Keyserlingk HJ, Wiederholt M (1986) Importance of HLA DR matching for corneal transplantation in high-risk cases. Cornea 5:139–143PubMedGoogle Scholar
  66. 66.
    Khaireedin R, Wachtlin J, Hopfenmüller W, Hoffman F (2003) HLA-A, HLA-B, and HLA-DR matching reduces the rate of corneal allograft rejection. Graefes Arch Clin Exp Ophthalmol 241:1020–1028CrossRefPubMedGoogle Scholar
  67. 67.
    Baggesen K, Lamm LU, Ehlers N (1996) Significant effect of high-resolution HLA-DRB1 matching in high-risk corneal transplantation. Transplantation 62:1273–1277CrossRefPubMedGoogle Scholar
  68. 68.
    Munkhbat B, Hagihara M, Sato T, et al. (1997) Association between HLA-DPB1 matching and 1-year rejection-free graft survival in high-risk corneal transplantation. Transplantation 63:1011–1016CrossRefPubMedGoogle Scholar
  69. 69.
    Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA, Armitage WJ (1994) Influence of donor and histocompatibility factors on corneal graft outcome. Transplantation 58:1210–1216PubMedGoogle Scholar
  70. 70.
    Morris PJ (1996) A critical review of immunosuppressive regimens. Transplant Proc 28(Suppl):37–40PubMedGoogle Scholar
  71. 71.
    Abrahams C, Gaillard V (1980) Instillation of steroids in the eye: its effect on lymphocytes in regional lymph nodes and in peripheral blood. S Afr Med J 57:993–995PubMedGoogle Scholar
  72. 72.
    Meyer PA, Watson PG, Franks W, Dubord P (1987) 'Pulsed’ immunosuppressive therapy in the treatment of immunologically induced corneal and scleral disease. Eye 1:487–495PubMedGoogle Scholar
  73. 73.
    Silverman ED, Myones BL, Miller JJ 3rd (1984) Lymphocyte sub-population alterations induced by intravenous megadose pulse methylprednisolone. J Rheumatol 11:287–290PubMedGoogle Scholar
  74. 74.
    Zweiman B, Atkins PC, Bedard PM, Flaschen SL, Lisak RP (1984) Corticosteroid effects on circulating lymphocyte subset levels in normal humans. J Clin Immunol 4:151–155CrossRefPubMedGoogle Scholar
  75. 75.
    Berge RJ, Sauerwein HP, Yong SL, Schellekens PT (1984) Administration of prednisolone in vivo affects the ratio of OKT4/OKT8 and the LDHisoenzyme pattern of human T lymphocytes. Clin Immunol Immunopathol 30:91–103CrossRefPubMedGoogle Scholar
  76. 76.
    Hill JC, Maske R, Watson P (1991) Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology 98:329–333PubMedGoogle Scholar
  77. 77.
    Hill JC, Ivey A (1994) Corticosteroids in corneal graft rejection; double versus single pulse therapy. Cornea 13:383–388PubMedGoogle Scholar
  78. 78.
    Lam DS, Wong AK, Tham CC, Leung AT (1998) The use of combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: a preliminary study. Eye 12:615–618PubMedGoogle Scholar
  79. 79.
    Hudde T, Minassian DC, Larkin DF (1999) Randomized controlled trial of corticosteroid regimens in endothelial corneal graft rejection. Br J Ophthalmol 83:1348–1352PubMedGoogle Scholar
  80. 80.
    Thompson JF, Chalmers DH, Wood RF, Kirkham SR, Morris PJ (1983) Sudden death following high-dose intravenous methylprednisolone. Transplantation 36:594–596PubMedGoogle Scholar
  81. 81.
    Mackay IR, Bignell JL, Smith PH, Crawford BA (1967) Prevention of corneal graft failure with the immunosuppressive drug azothioprine. Lancet 2:479–482CrossRefPubMedGoogle Scholar
  82. 82.
    Reinhard T, Reis A, Bohringer D, Malinowski M, Voiculescu A, Heering P, Godehardt E, Sunmacher R (2001) Systemic mycophenolate motefil in comparison with systemic cyclosporin A in highrisk keratoplasty patients: 3 years' results of randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 239:367–372PubMedGoogle Scholar
  83. 83.
    Hogan PG, Chen L, Nardone J, Rao A (2003) Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17:2205–2232CrossRefPubMedGoogle Scholar
  84. 84.
    Shepherd WFI, Coster DJ, Chin Foog TC, Rice NSC, Jones BR (1980) Effect of cyclosporin A on the survival of corneal grafts in rabbits. Br J Ophthalmol 64:148–153PubMedGoogle Scholar
  85. 85.
    Zhang EP, Schulte F, Bulfone-Paus S, Hoffman F (2000) The effect of corticosteroid and cyclosporin A on murine corneal allograft rejection. Graefes Arch Clin Exp Ophthalmol 238:525–530PubMedGoogle Scholar
  86. 86.
    Claerhout I, Beele H, Verstraete A, Van den Broecke C, Kestelyn P (2001) The effect of duration and timing of systemic cyclosporine therapy on corneal allograft survival in a rat model. Graefes Arch Clin Exp Ophthalmol 23:152–157Google Scholar
  87. 87.
    Hill JC (1994) Systemic cyclosporin in high-risk keratoplasty. Short-term versus long-term therapy. Ophthalmology 101:12833Google Scholar
  88. 88.
    Hill JC (1995) Systemic cyclosporin in high-risk keratoplasty: long-term results. Eye 9:422–428PubMedGoogle Scholar
  89. 89.
    Sundmacher R, Reinhard T, Heering P (1992) Six years' experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective study. Ger J Ophthalmol 1:432–436PubMedGoogle Scholar
  90. 90.
    Poon AC, Forbes JE, Dart JK, Subramaniam S, Bunce C, Madison P, Ficker LA, Tuft SJ, Gartry DS, Buckley RJ (2001) Systemic cyclosporin A in high-risk penetrating keratoplasties: a case-control study. Br J Ophthalmol 85:1465–1469Google Scholar
  91. 91.
    Inoue K, Kimura C, Amano S, Sato T, Fujjita N, Kagayo F, Kaji Y, Tsuru T, Araie M (2001) Long-term outcome of cyclosporine treatment following penetrating keratoplasty. Jpn J Ophthalmol 45:378–382CrossRefPubMedGoogle Scholar
  92. 92.
    Rumelt S, Berdusky V, Blum-Hareuveni T, Rehany V (2002) Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol 86:988–992CrossRefPubMedGoogle Scholar
  93. 93.
    Algros MP, Angonin R, Delbose B, Cahn JY, Kantelip B (2002) Danger of systemic cyclosporin for corneal grafts. Cornea 21:613–614CrossRefPubMedGoogle Scholar
  94. 94.
    Ippoliti G, Fronterre A (1987) Use of locally injected anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Prod 19:2579–2580Google Scholar
  95. 95.
    Ippoliti G, Fronterre A (1989) Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 21:3133–3134PubMedGoogle Scholar
  96. 96.
    Newman DK, Isaacs JD, Watson PG, Meyer PA, Hale G, Waldmann H (1995) Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Eye 9:564–569PubMedGoogle Scholar
  97. 97.
    Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, et al. (2000) Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 84:107–109CrossRefPubMedGoogle Scholar
  98. 98.
    Schmitz K, Hitzer S, Behrens-Baumann W (2002) Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmology 99:38–45Google Scholar
  99. 99.
    Thiel MA, Coster DJ, Williams KA (2003) The potential of antibody-based immunosuppressive agents for corneal transplantation. Immunol Cell Biol 81:93–105CrossRefPubMedGoogle Scholar
  100. 100.
    Thiel MA, Coster DJ, Standfield SD, et al. (2002) Penetration of engineered antibody fragments into the eye. Clin Exp Immunol 128:67–74CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Douglas J. Coster
  • Keryn A. Williams

There are no affiliations available

Personalised recommendations